Fulcrum Therapeutics (FULC) Change in Accured Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Change in Accured Expenses data on file, last reported at -$3.8 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.8 million, down 12.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $599000.0 (up 232.82% YoY), and the FY2025 annual result was $1.0 million, up 199.32% from the prior year.
• Change in Accured Expenses fell to -$3.8 million in Q1 2026 per FULC's latest filing, from $2.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.8 million in Q2 2022 and troughed at -$4.5 million in Q3 2022.
• A 5-year average of -$237823.5 and a median of $587000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses plunged 289.74% in 2022, then soared 525.16% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.6 million in 2022, then tumbled by 41.81% to $909000.0 in 2023, then plunged by 170.41% to -$640000.0 in 2024, then surged by 457.97% to $2.3 million in 2025, then tumbled by 264.38% to -$3.8 million in 2026.
• Business Quant data shows FULC's Change in Accured Expenses at -$3.8 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.